Mereo BioPharma (MREO) Receivables (2022 - 2023)
Mereo BioPharma (MREO) posted quarterly Receivables of $9.9 million for Q2 2023, up 452.55% on a QoQ basis from $1.8 million in Q4 2022.
Mereo BioPharma (MREO) Receivables (2022 - 2023) Analysis & Trends
Mereo BioPharma (MREO) has reported Receivables for 2 consecutive years, with $9.9 million the latest figure, recorded in Q2 2023.
- Quarterly Receivables changed N/A year-over-year to $9.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $9.9 million (changed N/A YoY) and the FY2022 annual result came in at $1.8 million, changed N/A from the prior year.
- Receivables improved to $9.9 million in Q2 2023 per MREO's latest filing, from $1.8 million in the prior quarter.
- Over the last five years, Receivables for MREO reached as high as $9.9 million in Q2 2023 and fell as low as $1.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Mereo BioPharma | 232.52 Mn | 232.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 9.88 Mn |
| Dec 31, 2022 | 1.79 Mn |